Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX15/2503 with Ipilimumab or Nivolumab in Resectable Metastatic Melanoma
NCT03769155Phase 1Active, not recruiting
- Sponsor
- Emory University
- Start
- Dec 2018
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pepinemab in melanoma (5 arms), sponsored by Emory University. Primary endpoint: Extent of CD8+ T cell infiltration up to 10 years. Started Dec 2018; status: active, not recruiting.
02
Drugs
pepinemab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03769155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769155.